國藥現代(600420.SH):阿奇黴素片、二羥丙茶鹼注射液通過一致性評價
格隆匯6月4日丨國藥現代(600420.SH)公佈,公司及全資子公司國藥集團容生製藥有限公司(簡稱國藥容生)分別收到國家藥品監督管理局核准簽發的《藥品補充申請批准通知書》,藥品名稱:阿奇黴素片、二羥丙茶鹼注射液。阿奇黴素是一種大環內酯類抗生素,臨牀上適用於敏感細菌所引起的感染,包括支氣管炎、肺炎等下呼吸道感染;皮膚和軟組織感染;急性中耳炎;鼻竇炎、咽炎、扁桃體炎等上呼吸道感染;沙眼衣原體所導致的單純性生殖器感染等。二羥丙茶鹼注射液適用於治療支氣管哮喘、喘息型支氣管炎、阻塞性肺氣腫等,緩解喘息症狀;也可用於因心源性肺水腫而致的喘息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.